Studying a ubiquinol–nicotinamide crystal structure
Mechanistic / preclinical evidence
Zhang et al. · 2023 · Pharmaceutics
Study details
- Evidence Type
- Solid-state characterization, laboratory tests and rat pharmacokinetics
- Studied Material / Formulation
- Experimental ubiquinol–nicotinamide cocrystal and the study’s ubiquinol comparator.
- Population
- Laboratory samples; rat PK n=12, six per group
- Dose
- Rat experiment: single 100 mg/kg; not a human dose
- Duration
- Stability: open conditions to 28 days; accelerated conditions to 6 months
- Main Findings
- A ubiquinol–nicotinamide cocrystal was characterized. Stability and dissolution differed from the tested ubiquinol crystal form under the study conditions.
- Limitations
- Material experiments and animal PK do not prove clinical benefit, human absorption superiority or shelf life of DR.MORGAN capsules. Commercial batch identity is not established by this paper.
- Product Relevance
- Mechanistic relevance
- DR.MORGAN finished product studied
- NO
This study was not conducted on the finished DR.MORGAN product.
Funding and disclosures
Natural Science Foundation of Shanghai; authors declare no conflict.